Emerging patient-specific treatment modalities in head and neck cancer - a systematic review
| Autor: | Elicin, O., Cihoric, N., Vlaskou Badra, E., Ozsahin, M. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Antibodies
Monoclonal/administration & dosage Antibodies Monoclonal/pharmacology Antineoplastic Agents/administration & dosage Antineoplastic Agents/pharmacology Biomarkers Tumor/metabolism Drug Development/methods Head and Neck Neoplasms/immunology Head and Neck Neoplasms/pathology Head and Neck Neoplasms/therapy Humans Immunotherapy/methods Precision Medicine/methods Protein Kinase Inhibitors/administration & dosage Protein Kinase Inhibitors/pharmacology Adoptive cell therapy CAR T-cells CRISPR cancer vaccine clinical trials gene editing head and neck cancer squamous-cell carcinoma targeted therapy |
| Zdroj: | Expert opinion on investigational drugs, vol. 28, no. 4, pp. 365-376 |
| Popis: | Head and neck cancer (HNC) is an immunosuppressive disease that demonstrates heterogeneous molecular characteristics and features of tumor-host interaction. Beside radiotherapy and surgery, the current standard of care in systemic treatment involves the use of cytotoxic chemotherapy, monoclonal antibodies (mAbs), and tyrosine kinase inhibitors (TKIs). There are also other modalities being developed under the category of immunotherapy, but they are overshadowed by the recent advancements of immune checkpoint inhibitors. Areas covered: This systematic review covers recent advancements in 'patient-specific' treatment modalities, which can be only administered to a given patient. Expert opinion: Currently, patient-specific treatment modalities in HNC mainly consist of active immunotherapy using adoptive cell therapies and/or gene engineered vectors. Despite the slow pace of development, the interest continues in these treatment modalities. The future of HNC treatment is expected to be guided by biomarkers and personalized approaches with tailored combinations of local treatments (radiotherapy, surgery), systemic agents and immune system modulation. Systematic research is required to generate robust data and obtain a high-level of evidence for the effectiveness of such treatment modalities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|